Follow on Google News Industry News News By Location Country(s) Industry News
Follow on Google News | FyMed Expands Its Drug Development Portfolio Through Innovative Personalized Medicine StrategiesFyMed, Inc., a biopharmaceutical company today announced strategic and operational expansion plans following the successful completion of major preclinical drug studies utilizing proprietary companion diagnostics and prognostic technologies.
By: FyMed Inc “This expansion will enable us to continue to discover and develop novel linked pharmaceutical- FyMed has developed a portfolio of products by opportunistically leveraging proprietary advanced methodologies in pharmacogenomics and proteomics and effectively integrating this with the drug discovery process. These approaches offered significant advantages to the Company in the development of novel and improved targeted products for both expansive and specialized pharmaceutical markets. “Current personalized medicine based strategies are limited in market size and value due to inherent differences in patient heterogeneity and pharmacodynamics,” FyMed has utilized these methodologies for several drugs in current development. The Company has successfully completed preclinical studies with three major candidates, demonstrating the potential of significant impact in the pain, inflammation, and the infectious disease market. The Company plans to proceed with clinical trials, and is simultaneously conducting several preclinical studies for various indications. FyMed’s intended expansions include the strategic application of integrative clinical, pharmacogenomic, proteomic, and molecular phenotypic data with the decisive implementation of focused drug-centric models of companion diagnostics and prognostic driven modalities. Implementation of these approaches will enable the Company to sustain innovation, and lead to more effective and safer therapies in favor of product approval. About FyMed, Inc. FyMed, Inc. is a biopharmaceutical company with a growing portfolio of novel and improved pharmaceuticals enhanced through ultra-sensitive next generation targeted companion diagnostics and prognostics. Leading innovations in personalized medicine has enabled FyMed to effectively balance technological innovation with scientific discovery, creating tools that can productively integrate with drug development and capitalize on key market deficiencies. Safe Harbor Statement To the extent any statements made in this document contain information that is not historical, this news release contains "forward-looking statements" within the meaning of Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of the words "intends," "plans," "will," "potential," Contact: Media Relations, FyMed, Inc., 3422 Old Capitol, Ste 1610, Wilmington, DE 19808 Tel: 302-722-5225, Email: media@fymed.com Press Release: http://www.fymed.com/ Web: http://www.fymed.com End
Account Email Address Account Phone Number Disclaimer Report Abuse
|
|